Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.

By Yogeshkumar Malam, M. Loizidou, Alexander M. Seifalian. TIPS - Trends in Pharmacological Sciences, 2009

1,267 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “Albumin seems to help endothelial transcytosis of proteinbound and unbound plasma constituents via the binding to a cellsurface receptor (gp60) [7].”
Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors (2017, background): “SLNs provide a highly lipophilic lipid matrix for drugs to be dispersed or dissolved.(8) A wide variety of solid lipids including mono-, di- and triglycerides; free fatty acids; free fatty alcohols; waxes and steroids have been utilized for the preparation of SLNs.”
Enzyme-responsive nanoparticles for drug release and diagnostics. (2012, background): “However, liposomes are rapidly cleared from the blood stream by opsonization unless their outer shell is modified with polymers such as PEG [43].”
A Review of Curcumin and Its Derivatives as Anticancer Agents (2019, background): “Recent advances in liposome formulations have resulted in improved treatment for drug-resistant tumors and reduced toxicity [58].”